BIOADAPTIVES, INC.

The Company’s History

BioAdaptives, Inc., (“BioAdaptives,” the “Company,” “we” or “us”) was incorporated in the State of Delaware on April 19, 2013, as APEX 8 Inc. From inception through October 21, 2013, the Company was in the developmental stage and conducted virtually no business operations, other than organizational activities and preparation of a registration statement on Form 10-12g (the “Registration Statement”), which was filed with the U.S. Securities and Exchange Commission on May 3, 2013. On June 11, 2013, the SEC staff informed the Company that it had no further comments.

On January 10, 2014, the SEC notified the Company that the registration statement was effective. On July 9, 2014, the Company’s shares commenced trading in the Over-the-Counter market under the trading symbol BDPT.

On March 31, 2017, the Company filed Form 15-15D with the SEC, terminating its status as an SEC-reporting company; it was current in its Continuous Disclosure obligations at that time. The Company continued to provide financial and other reports to shareholders and the public using the Alternative Reporting System operated by OTC Markets Group, Inc. Its shares continued to trade in the OTC market, and it also continued to execute its business plan.

On May 10, 2019, the Company filed Form 10-12g with the SEC, re-entering the Continuous Disclosure program and registering its common stock under Section 12(g) of the Securities Exchange Act of 1934. On August 1, 2019, the SEC staff informed the Company that it had no further comments on this filing.

On September 11, 2019, the Company appointed Robert Ellis as President and Ron Lambrecht as Chief Financial Officer. Dr. Jacobs remained Chief Executive Officer.

On February 6, 2020, the Board of Directors exercised its authority under the Delaware General Corporations Law to establish its Series A Preferred Stock. Series A has enhanced voting and conversion privileges and can be used by the Company to settle recorded debt or exchange for new product rights or techniques. On this same day, the Board of Directors authorized an increase in the Company’s authorized common stock from 100,000,000 to 200,000,000; holders of a majority of the Company’s common shares consented to the increase.

On January 26, 2022, the Board of Directors exercised its authority under the Delaware General Corporations Law to establish its Series B Preferred Stock. Series B has enhanced voting and conversion privileges and can be used by the Company to acquire ownership of intellectual property rights and other assets. On this same day, the Board of Directors authorized an increase in the Company’s authorized common stock from 200,000,000 to 750,000,000; this increase received the consent of the holders of a majority of the Company’s common shares.

On March 18, 2022, the Company filed Form 1-A with the Securities and Exchange Commission covering a plan to sell up to 200,000,000 shares of common stock at prices between .005 and .01 per share. This was amended on October 7, 2022, to 250,000,000 shares of common stock at 0.001.

On February 28, 2023, the Board of Directors exercised its authority under the Delaware General Corporation Law to increase the Company’s authorized common stock from 750,000,000 to 1,250,000,000; the holders of a majority of the Company’s shares consented to the increase.

On May 15, 2024, Dr. Edward Jacobs retired from the Company and was succeeded by Mr. James E. Kneer as Chairman and CEO. As of May 27, 2024, Mr. Gimhana Dissanayake joined him as a Director of the Company.

On October 28, 2024, the Board unanimously resolved to proceed with a reverse split of 1 for 300 shares.

On November 21, 2024, the reverse was completed

On December 3, 2024, the Board approved a One-for-One Stock Dividend to holders of common stock.

The Company’s Business

Overview

BioAdaptives’ core business is investigating, marketing, and distributing natural plant, fungi, and algal-based products and medical devices that improve health and wellness for humans and animals. The company emphasizes weight control, antiviral function, and anti-aging properties. BioAdaptives is reformulating its entire product line and will introduce new products in the first quarter of 2025.

The Company’s current products in development include a weight management supplement in a Human Clinical trial, Zeranovia™. Zeranovia™ is made of natural ingredients and uses proprietary methods of optimizing the availability of nutrients in foods and beverages. The trials have shown better than expected results, with the procedure positively affecting participants, with consistent weight loss and minimal side effects. Zeranovia™ empowers users to lose weight while maintaining more lean muscle mass. Based on current results, Zeranovia™ is expected to be introduced commercially in the second quarter of 2025.

Xcellara™ regenerative stem cell activator is in production and is expected to be sold commercially in April 2025. PawPa™ Regen, the canine treat stem cell activator, will be available for delivery in April 2025. PawPa™ Regen supports anti-aging and wellness. These formulations are based upon extensive trials on humans, dogs, horses, hogs, and mice. The canine products are all in the form of treats, making delivery and dosing very simple and effective.

At the request of a member of the BioAdaptives Board of Advisors, BioAdaptives developed an advanced nootropic, MyndMed™, it focuses on diverse pathways, delivering acetylcholine (focus), dopamine (mood), GABA (calm), antioxidants (protection), and energy (mitochondria) while avoiding tolerance and extending impact. MyndMed™ is designed to improve memory, learning, cognitive enhancement, mood support, neuroprotection, neuroplasticity, and stress resilience.

We continue researching and developing new nutraceutical products for humans and animals to solve problems and deliver the best-in-class products. Our products are unique, well-designed, and proven to bring benefits, not just copying others.

Market and Marketing

BioAdaptives Inc. has developed a robust Direct to Consumer (DTC) digital marketing campaign to connect directly with its target audience. Leveraging platforms like social media, email marketing, and a user-friendly website, the company promotes its supplement products with engaging content tailored to health-conscious consumers. Through targeted ads, informative blog posts, and compelling calls-to-action, BioAdaptives ensures its messaging resonates, driving awareness and conversions while fostering a community around wellness and natural health solutions.

In addition to its DTC efforts, BioAdaptives has forged strategic partnerships within the telehealth industry to enhance its product offerings. By aligning its supplements as both companion products and standalone solutions, the company integrates seamlessly with telehealth platforms, providing participants with accessible, science-backed options to support their wellness journeys. These collaborations not only expand BioAdaptives’ reach but also position our products as trusted recommendations within virtual healthcare ecosystems, capitalizing on the growing demand for telehealth services.

Finally, BioAdaptives employs a dynamic affiliate marketing program, partnering with companies and individual influencers who boast large social media followings and proven success in the supplement industry. These affiliates, carefully selected for their credibility and performance, promote BioAdaptives’ products through authentic endorsements, affiliate links, and promo codes. This strategy amplifies brand visibility, drives sales, and builds trust among niche audiences, leveraging the influence of established voices in the health and wellness space to accelerate growth.

Manufacturing

All of the Company’s nutraceutical products are considered dietary supplements or natural foods, and we carefully avoid making health, drug, or disease cure claims that could trigger regulatory compliance issues and affect our ability to market BioAdaptives products. Our active ingredients are all plant, fungi, or algal-based and sourced worldwide from reputable suppliers who employ stringent compliance and sustainable agriculture practices.

BioAdaptives actively investigates new products, techniques, and novel applications of existing products or technology in our research. The Company’s research has focused on investigating all-natural supplement formulations that activate primitive cells, including stem cells and their derivatives, and natural ingredients that encourage stem cell proliferation. In 2022, the Company started a product line utilizing algae and mushrooms.

With regard to medical devices, in April 2024, we purchased the Lungflute™ from the sole US affiliate of the patent holder. We do not expect to develop any direct capability to manufacture medical devices for numerous reasons, including a lack of capital and the fact that the amortized cost of such facilities, if we were to construct or acquire them, is generally far higher compared to the cost of purchasing a finished product. We operate as a Research and Development nutraceutical company.

Employees

As of May 2024, the Company has one full-time executive employee. We retain hourly labor as needed and professional consultants to operate our business. The company’s management expects to use outside consultants, attorneys, and accountants as necessary. The need for additional employees and their availability will be addressed when deciding whether to acquire or participate in specific business opportunities.